SK280114B6 - Mutantný hil-4 proteín a terapeutické činidlo túto - Google Patents

Mutantný hil-4 proteín a terapeutické činidlo túto Download PDF

Info

Publication number
SK280114B6
SK280114B6 SK554-94A SK55494A SK280114B6 SK 280114 B6 SK280114 B6 SK 280114B6 SK 55494 A SK55494 A SK 55494A SK 280114 B6 SK280114 B6 SK 280114B6
Authority
SK
Slovakia
Prior art keywords
protein
hil
amino acid
replaced
mutant
Prior art date
Application number
SK554-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK55494A3 (en
Inventor
Walter Sebald
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6444719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK280114(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of SK55494A3 publication Critical patent/SK55494A3/sk
Publication of SK280114B6 publication Critical patent/SK280114B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK554-94A 1991-11-13 1992-11-13 Mutantný hil-4 proteín a terapeutické činidlo túto SK280114B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4137333A DE4137333A1 (de) 1991-11-13 1991-11-13 Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
PCT/EP1992/002614 WO1993010235A1 (de) 1991-11-13 1992-11-13 Menschliche il-4 mutantenproteine

Publications (2)

Publication Number Publication Date
SK55494A3 SK55494A3 (en) 1994-12-07
SK280114B6 true SK280114B6 (sk) 1999-08-06

Family

ID=6444719

Family Applications (1)

Application Number Title Priority Date Filing Date
SK554-94A SK280114B6 (sk) 1991-11-13 1992-11-13 Mutantný hil-4 proteín a terapeutické činidlo túto

Country Status (16)

Country Link
US (1) US5723118A (hu)
EP (1) EP0613499B2 (hu)
JP (2) JP3470970B2 (hu)
KR (1) KR100276410B1 (hu)
AT (1) ATE163196T1 (hu)
AU (1) AU671960B2 (hu)
CA (1) CA2123315C (hu)
CZ (1) CZ283467B6 (hu)
DE (2) DE4137333A1 (hu)
DK (1) DK0613499T4 (hu)
ES (1) ES2112340T5 (hu)
GR (1) GR3026600T3 (hu)
HU (1) HU217326B (hu)
NO (1) NO312707B1 (hu)
SK (1) SK280114B6 (hu)
WO (1) WO1993010235A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
IL126995A0 (en) * 1996-06-14 1999-09-22 Bayer Ag T-cell selective interleukin-4 agonists
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
DE10022258A1 (de) 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1314739A1 (en) * 2001-11-22 2003-05-28 Bayer Ag Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
RU2009101783A (ru) * 2006-06-21 2010-07-27 Апогеникс Гмбх (De) Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
CA2656135A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
EP0327283B1 (en) * 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels

Also Published As

Publication number Publication date
NO312707B1 (no) 2002-06-24
EP0613499B2 (de) 2005-03-30
EP0613499B1 (de) 1998-02-11
CA2123315C (en) 2003-06-17
KR100276410B1 (ko) 2000-12-15
SK55494A3 (en) 1994-12-07
DK0613499T4 (da) 2005-04-18
CA2123315A1 (en) 1993-05-27
NO941681L (no) 1994-05-06
US5723118A (en) 1998-03-03
EP0613499A1 (de) 1994-09-07
NO941681D0 (no) 1994-05-06
ES2112340T3 (es) 1998-04-01
HU9401369D0 (en) 1994-08-29
ES2112340T5 (es) 2005-10-16
HUT66826A (en) 1995-01-30
GR3026600T3 (en) 1998-07-31
JPH07501522A (ja) 1995-02-16
AU2928292A (en) 1993-06-15
ATE163196T1 (de) 1998-02-15
DE4137333A1 (de) 1993-05-19
CZ283467B6 (cs) 1998-04-15
CZ118594A3 (en) 1994-12-15
JP2003174894A (ja) 2003-06-24
AU671960B2 (en) 1996-09-19
JP3470970B2 (ja) 2003-11-25
DE59209196D1 (de) 1998-03-19
HU217326B (hu) 1999-12-28
WO1993010235A1 (de) 1993-05-27
DK0613499T3 (da) 1998-09-23

Similar Documents

Publication Publication Date Title
SK280114B6 (sk) Mutantný hil-4 proteín a terapeutické činidlo túto
Henderson et al. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma
Nardelli et al. Regulatory effect of IFN-κ, a novel type I IFN, on cytokine production by cells of the innate immune system
Keane-Myers et al. Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12
Tunon‐De‐Lara et al. Dendritic cells in normal and asthmatic airways: expression of the α subunit of the high affinity immunoglobulin E receptor (FcεRI‐α)
Perkins et al. IL-4 induces IL-13–independent allergic airway inflammation
Hsu et al. Immunoprophylaxis of allergen–induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization
Hultner et al. In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9
Ohta et al. Diesel exhaust particulate induces airway hyperresponsiveness in a murine model: essential role of GM-CSF
US8110187B2 (en) Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US5324510A (en) Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
Virchow et al. CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma
CA2556425A1 (en) Methods of modulating il-23 activity; related reagents
EP1817337A1 (en) Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis
EP1379647B1 (en) Antagonist antibodies of a mammalian cytokine or its receptor for the treatment of allergy
EP0387701A1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US6433157B1 (en) Polynucleotides encoding T-cell selective interleukin-4 agonists
SK286439B6 (sk) MCP-2 skrátený na aminokonci, DNA molekuly, expresný vektor, hostiteľská bunka, rekombinantný spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom a jeho použitie
Tanaka et al. Time course study on the development of allergen-induced airway remodeling in mice: the effect of allergen avoidance on established airway remodeling
EP0912741B1 (en) T-cell selective interleukin-4 agonists
Barbarin et al. Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis
Dentener et al. Characterization of two monoclonal antibodies directed against bactericidal/permeability-increasing protein
JP4394931B2 (ja) ヒトインターロイキン４およびヒトインターロイキン１３のアンタゴニストであるペプチド
Kagawa Contribution of human pulmonary macrophage-derived cytokines to asbestos-induced lung inflammation and fibrosis
Cytokines IL-5 Is the Predominant Eosinophil-adive Cytokine in the Antigen-induced Pulmonary Late-phase Readion

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20121113